CXCL10 As a Biomarker Of ILD in Patients WithRA

Assiut University

Status: Unknown

Conditions: Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Treatments: Diagnostic Test: serum cxcl10 by ELISA

Study type: Interventional

Funder types: Other

Identifiers

NCT04356066

zahraa

Details and patient eligibility

About

Rheumatoid arthritis is a chronic inflammatory disease that affects the joints, causing symmetric pain, stiffness, swelling, and limited motion and function of multiple joints, its fibro inflammatory manifestations may develop in other organs.

Full description

Rheumatoid arthritis is complicated by lung manifestations, such as interstitial lung disease which is the most common cause of morbidity and mortality in rheumatoid arthritis patients. Rheumatoid arthritis-interstitial lung disease is a progressive fibrotic disease of the lung parenchyma that includes a broad spectrum of disorders such as nonspecific interstitial pneumonia, usual interstitial pneumonia , desquamative interstitial pneumonia, cryptogenic organizing pneumonia, diffuse alveolar damage, acute interstitial pneumonia, and lymphocytic interstitial pneumonia . Rheumatoid arthritis-interstitial lung disease in which available data indicate that dysregulated inflammatory cascades can elaborate a host of cytokines, chemokines, and growth factors that collectively promote epithelial and endothelial cell damage, angiogenesis, fibroblast differentiation/proliferation, and lung fibrosis . Given the clinical implications of putative signaling cascades involved in these processes, biomarkers that can be used to clarify disease pathogenesis and identify factors governing disease progression are clearly needed .

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult rheumatoid arthritis patients who fulfilled the 2010 American College of Rheumatology/European league against rheumatism criteria for the classification of Rheumatoid Arthritis.
2. Adult rheumatoid arthritis patients with interstitial lung disease.

Exclusion criteria

1. Individuals with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, scleroderma, spondyloarthritis and inflammatory bowel disease).
2. Individuals with hepatitis, Rhinovirus infection, cerebral malaria.
3. Individuals with colorectal carcinoma, syndrome of frailty, vetiligo.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

80 participants in 1 patient group

Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise

Other group

Description:

* History taking: age, sex, disease duration, history of present illness, drug intake, past and family history. * Physical examination including thorough clinical examination. * Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018).

Treatment:

Diagnostic Test: serum cxcl10 by ELISA